JESSUP C, WALLACE T, GHANNOUM M; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 546 (abstract no. 163).
Ctr. for Med. Myocology, Case Western Reserve Univ., Cleveland, OH
Drug interactions can often occur when multiple therapies are used concomitantly. It is critically important to evaluate such interactions, as the clinically altered response may very well be synergistic, antagonistic, toxic, or not clinically significant at all. In this study we evaluated the in vitro susceptibility effects of using Nyotran in combination with conventional antifungals and antibiotics. Three isolates each of Candida albicans, Candida glabrata, Candida krusei, Cryptococcus neoformans and Aspergillus fumigatus were tested. Susceptibility testing was performed in a broth microdilution assay slightly modified from the NCCLS M27-A format, in RPMI-1640 medium buffered at pH7, incubated 48h at 35degrees C. Combination studies were done in a checkerboard design and analyzed by calculation of the Fractional Inhibitory Concentration Index (FICI). For Nyotran and amphotericin B, The endpoint was defined as the lowest concentration of drug that caused at least 100% growth inhibition as compared to the growth control well. All other drugs had endpoints defined as the lowest concentration of drug that caused at least 80% growth inhibition as compared to the growth control well. Synergy was defined by any FICI 2.0. Additive behavior was recorded as 1 < FICI < 0.5, while indifference was FICI= 1.2. The data showed that Nyotran in combination with amphotericin B was synergistic against 2/ 3 and additive against 1/3 Candida glabrata isolates, was additive in combination with itraconazole or flucytosine against three Candida krusei isolates and was additive in combination with amphotericin B against 2/3 Aspergillus fumigatus isolates. There were sporadic additive results with other fungi, but the remainder of the results showed indifferent interactions. There were no antagonistic responses. These data indicate that Nyotran can be used in combination with other drugs that are commonly present in fungally infected patients.
Publication Types:
Keywords:
- Amphotericin B
- Anti-Bacterial Agents
- Antifungal Agents
- Antiviral Agents
- Aspergillus fumigatus
- Candida
- Candida albicans
- Cryptococcus neoformans
- Drug Interactions
- Flucytosine
- Fungi
- Humans
- In Vitro
- Itraconazole
- Liposomes
- Nystatin
Other ID:
UI: 102246745
From Meeting Abstracts